Merck to Buy Idenix for $3.9B for Hepatitis C Drugs

June 9 (Bloomberg) -- Merck & Co. agreed to buy Idenix Pharmaceuticals Inc. for about $3.85 billion to add experimental drugs to treat hepatitis C. Adam Johnson reports on Bloomberg Television’s “Bloomberg Surveillance.” (Source: Bloomberg)
Central Banks Were Printing $130B a Month: Michele
33:47 - JPMorgan Global Chief Investment Officer of Fixed Income Bob Michele discusses central banks monetary policies, liquidity and the markets. He speaks on “Bloomberg Surveillance.” (Source: Bloomberg)
  • Bashar al-Assad: Charlie Rose (03/31)
  • Iran Nuclear Talks Enter Final Day
  • Iran Standoff Has Lasted 12 Years